Study of Mevrometostat for Advanced Prostate Cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of prostate cancer called adenocarcinoma (not small cell).
- Your cancer has spread to your bones or soft tissue (like lymph nodes).
- Your cancer is still growing despite hormone therapy for castration.
- You are in good physical condition (ECOG score 0 or 1) and expected to live at least 12 more months.
- You have not had any treatment for this stage of cancer (metastatic castration-resistant) except for certain earlier therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
This study tests a new drug (BMS-986460) for people with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the drug can shrink or slow the cancer.
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
This study tests a new drug called mevrometostat combined with enzalutamide in men whose prostate cancer has spread and is no longer responding to previous hormone-blocking treatments. The goal is to see if adding mevrometostat helps slow cancer growth when enzalutamide alone is no longer working.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.